Accessibility Menu
Rapid Micro Biosystems logo

Rapid Micro Biosystems(NASDAQ) RPID

Market Cap$105.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-90%
5 Year-91%
1 Year-36%
1 Month+23%
$2.13
-0.23%
-0.01Today
After hours$2.10-$0.02 (-1.18%)
Rapid Micro Biosystems last closing stock price
MetricPriceDate
Last closeUSD 2.122026-08-03
Rapid Micro Biosystems stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.47%USD 2.012026-07-27
1 month+23.26%USD 1.722026-07-02
3 month-14.52%USD 2.482026-05-05
Year to date-26.9%USD 2.902025-12-31
1 year-35.95%USD 3.312025-08-01
3 year+130.43%USD 0.922023-08-04
5 year-91.39%USD 24.622021-08-04
Since inception-90.05%USD 21.402021-07-15

Rapid Micro Biosystems Financials at a Glance

Market Cap

$105.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$34.38M

Net Income (TTM)

-$50.14M

EPS (TTM)

-$1.12

P/E Ratio

-1.90

Dividend

$0.00

Beta (Volatility)

1.29 (Average)

Price

$2.13

Volume

119,040

Open

$2.16

Previous Close

$2.12

Daily Range

$2.04 - $2.20

52-Week Range

$1.66 - $4.94

Estimated Earnings Date

Aug 7, 2026

RPID News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rapid Micro Biosystems

Rapid Micro Biosystems creates technology that tests for contamination in pharmaceutical manufacturing. Their Growth Direct platform automates quality control testing for medicines and vaccines. The Growth Direct platform detects harmful microbes at least 50% faster than traditional manual methods.

What's in Their Lab Toolkit

Growth Direct system: Automated platform that detects microbial contamination in pharmaceutical products using imaging technology.

Proprietary consumables: Single-use testing materials designed specifically for the Growth Direct system.

Software integration: Lab information management system that connects testing results with broader quality control systems.

Support services: Technical training, installation, verification, and ongoing customer support for system users.

Testing applications: Solutions for environmental monitoring, water testing, bioburden analysis, and sterility release testing.

Building a Cleaner Future

Launched rapid sterility application in Q2 2024 that reduces testing time to 1-3 days.

Established global distribution partnership with MilliporeSigma in February 2025.

Completed initial public offering on July 15, 2021, transitioning to publicly traded company.

Why Lab Techs Might Smile

The Growth Direct platform reduces manual testing steps by 85%, combining robotic automation with optical imaging and algorithmic analysis. The company's intellectual property portfolio as of December 31, 2024, comprises 10 U.S. patents and 53 foreign patents protecting its automated microbial detection technology.

Five Quick Quality Checks

Global installed base of 162 Growth Direct systems as of December 31, 2024.

Customer base includes 70% of the top twenty pharmaceutical companies worldwide as measured by revenue.

Improved gross margins from -3% to 12% between Q4 2023 and Q4 2024.

Held $50.7 million in cash, cash equivalents and short-term investments as of December 31, 2024.

Reported net losses of $46.9 million in CY2024, improved from $52.5 million in CY2023.

Bottom Line

Rapid Micro Biosystems offers specialized technology that modernizes quality testing in pharmaceutical manufacturing. Despite ongoing financial losses, the company continues improving operational efficiency while serving major pharmaceutical clients with its automated contamination detection platform.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

171

CEO

Robert Spignesi, MBA

Website

www.rapidmicrobio.com

Headquarters

Lexington, MA 02421, US

RPID Financials

Key Financial Metrics (TTM)

Gross Margin

12.40%

Operating Margin

-144.21%

Net Income Margin

-145.81%

Return on Equity

-131.52%

Return on Capital

-83.03%

Return on Assets

-80.39%

Earnings Yield

-52.63%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$105.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

49.82M

Volume

119.04K

Avg. Volume

179.99K

Financials (TTM)

Gross Profit

$4.26M

Operating Income

-$49.58M

EBITDA

-$45.12M

Operating Cash Flow

-$37.06M

Capital Expenditure

-$925.00K

Free Cash Flow

-$37.98M

Cash & ST Invst.

$22.95M

Total Debt

$23.71M

Rapid Micro Biosystems Performance Analysis

Rapid Micro Biosystems annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 17,133,000-26.3%
20232023-12-31USD 22,519,00031.4%
20242024-12-31USD 28,051,00024.6%
20252025-12-31USD 33,587,00019.7%
Rapid Micro Biosystems sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-300.8%
Q32025-09-307.9%
Q42025-12-3143.9%
Q12026-03-31-29.1%
Rapid Micro Biosystems annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.43-23.9%
20232023-12-31USD -1.22-14.9%
20242024-12-31USD -1.08-11.8%
20252025-12-31USD -1.05-2.0%
Rapid Micro Biosystems sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-3.8%
Q32025-09-307.4%
Q42025-12-31-12.0%
Q12026-03-31-10.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$8.00M

+11.1%

Gross Profit

$371.00K

-8.2%

Gross Margin

4.64%

N/A

Market Cap

$105.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$617.67K

N/A

Employees

171

N/A

Net Income

-$14.28M

-26.7%

EBITDA

-$12.92M

-24.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$22.95M

-44.9%

Total Debt

$23.71M

+303.5%

Accounts Receivable

$6.49M

+43.3%

Inventory

$17.45M

-15.8%

Long Term Debt

$22.39M

+382.4%

Short Term Debt

$1.32M

+6.9%

Return on Assets

-80.39%

N/A

Return on Invested Capital

-1.15%

N/A

Free Cash Flow

-$15.45M

-64.7%

Operating Cash Flow

-$15.06M

-66.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LUCDLucid Diagnostics Inc.
$0.97+11.11%
OWLTOwlet, Inc.
$5.43+5.64%
VANIVivani Medical, Inc.
$1.33+3.91%
RCELAvita Medical Inc.
$4.62+5.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$23.99+0.01%
TQQQProShares Trust - ProShares UltraPro Qqq
$67.96+0.05%
PLTRPalantir Technologies
$125.65+0.02%
INTCIntel
$91.00+0.01%

Questions About RPID

What is the current price of Rapid Micro Biosystems?

Rapid Micro Biosystems is trading at $2.12 per share.

What is the 52-week range for Rapid Micro Biosystems?

Over the past 52 weeks, Rapid Micro Biosystems has traded between $1.66 and $4.94.

How much debt does Rapid Micro Biosystems have?

As of the most recent reporting period, Rapid Micro Biosystems reported total debt of $23.71M.

How much cash does Rapid Micro Biosystems have on hand?

Rapid Micro Biosystems reported $13.82M in cash and cash equivalents in its most recent financial results.

What is Rapid Micro Biosystems’s dividend yield?

Rapid Micro Biosystems does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services